Press Releases Keyword Search Year None20212020201920182017 Date Title 10/22/21 Aadi Bioscience Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncology 10/19/21 Aadi Bioscience to Participate in H.C. Wainwright’s 2nd Annual Precision Oncology Conference 2021 10/06/21 Aadi Bioscience to Present New Preclinical Data on nab-Sirolimus (ABI-009) at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 09/20/21 Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer 09/13/21 Aadi Bioscience Appoints Emma Reeve to its Board of Directors 08/26/21 Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement 08/11/21 Aerpio Reports Second Quarter 2021 Financial Results and Provides Business Update 07/26/21 Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO™ for the Treatment of Advanced Malignant PEComa 07/07/21 Aadi Bioscience to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference 06/04/21 Aerpio Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting 06/04/21 Aadi Bioscience Presents Emerging Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 or TSC2 Inactivating Alterations from a Multi-Institution Expanded Access Program at ASCO 2021 05/19/21 Aerpio Provides Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting 05/19/21 Aadi Bioscience Announces Preliminary Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 and TSC2 Alterations from a Multi-Institution Expanded Access Study to be Presented at ASCO 2021 Virtual Meeting 05/17/21 Aerpio Reports First Quarter 2021 Financial Results and Provides Business Update 05/17/21 Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement 03/11/21 Aerpio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update 03/05/21 Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’s Razuprotafib in I-SPY COVID Trial 01/11/21 Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARRO™) in Greater China 01/05/21 Aerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 Trial
Press Releases Keyword Search Year None20212020201920182017 Date Title 10/22/21 Aadi Bioscience Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncology 10/19/21 Aadi Bioscience to Participate in H.C. Wainwright’s 2nd Annual Precision Oncology Conference 2021 10/06/21 Aadi Bioscience to Present New Preclinical Data on nab-Sirolimus (ABI-009) at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 09/20/21 Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer 09/13/21 Aadi Bioscience Appoints Emma Reeve to its Board of Directors 08/26/21 Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement 08/11/21 Aerpio Reports Second Quarter 2021 Financial Results and Provides Business Update 07/26/21 Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO™ for the Treatment of Advanced Malignant PEComa 07/07/21 Aadi Bioscience to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference 06/04/21 Aerpio Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting 06/04/21 Aadi Bioscience Presents Emerging Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 or TSC2 Inactivating Alterations from a Multi-Institution Expanded Access Program at ASCO 2021 05/19/21 Aerpio Provides Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting 05/19/21 Aadi Bioscience Announces Preliminary Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 and TSC2 Alterations from a Multi-Institution Expanded Access Study to be Presented at ASCO 2021 Virtual Meeting 05/17/21 Aerpio Reports First Quarter 2021 Financial Results and Provides Business Update 05/17/21 Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement 03/11/21 Aerpio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update 03/05/21 Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’s Razuprotafib in I-SPY COVID Trial 01/11/21 Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARRO™) in Greater China 01/05/21 Aerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 Trial
10/22/21 Aadi Bioscience Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncology
10/19/21 Aadi Bioscience to Participate in H.C. Wainwright’s 2nd Annual Precision Oncology Conference 2021
10/06/21 Aadi Bioscience to Present New Preclinical Data on nab-Sirolimus (ABI-009) at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
08/26/21 Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement
07/26/21 Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO™ for the Treatment of Advanced Malignant PEComa
06/04/21 Aerpio Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting
06/04/21 Aadi Bioscience Presents Emerging Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 or TSC2 Inactivating Alterations from a Multi-Institution Expanded Access Program at ASCO 2021
05/19/21 Aadi Bioscience Announces Preliminary Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 and TSC2 Alterations from a Multi-Institution Expanded Access Study to be Presented at ASCO 2021 Virtual Meeting
03/11/21 Aerpio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
03/05/21 Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’s Razuprotafib in I-SPY COVID Trial
01/11/21 Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARRO™) in Greater China
01/05/21 Aerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 Trial
